Role of melatonin in the pathophysiology of migraine: Implications for treatment

CNS Drugs

Volumn 20, Issue 5, 2006, Pages 343-350

  Vogler, Barbara ^a   Rapoport, Alan M ^b,c,g   Tepper, Stewart J ^b,d   Sheftell, Fred ^b,e   Bigal, Marcelo E ^b,f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NEUROTRANSMITTER; VALPROIC ACID;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BRAIN DEPTH STIMULATION; CLUSTER HEADACHE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; ENZYME INHIBITION; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOTHALAMUS DISEASE; INHIBITION KINETICS; MENSTRUAL CYCLE; MIGRAINE; MIGRAINE AURA; NERVE STIMULATION; PINEAL BODY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TENSION HEADACHE; THALAMUS MIDLINE NUCLEUS; TRIGEMINUS GANGLION;

ANIMALS; CLINICAL TRIALS; HUMANS; MELATONIN; MIGRAINE DISORDERS;

EID: 33646798058     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620050-00001     Document Type: Review

References (32)

1. Brun J, Claustrat B, Saddier P, et al. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995; 15: 136-9
2. Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005; 25: 403-11
3. Zurak N. Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. Cephalalgia 1997; 17: 723-8
4. Silberstein SD. Advances in understanding the pathophysiology of headache. Neurology 1992 Mar; 42 (3 Suppl. 2): 6-10
5. Ramadan NM. Targeting therapy for migraine: what to treat? Neurology 2005 May 24; 64 (10 Suppl. 2): S4-8
6. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004; 25: 177-95
7. Moller M, Baeres FMM. The anatomy and innervation of the mammalian pineal gland. Cell Tissue Res. 2002 Jul; 309 (1): 139-50
8. Peres MF, Sanchez del Rio M, Seabra MLV, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001; 71: 747-51
9. Perreau-Lenz S, Kalsbeek A, Van Der Vliet J, et al. In vivo evidence for a controlled offset of melatonin synthesis at dawn by the suprachiasmatic nucleus in the rat. Neuroscience 2005; 130 (3): 797-803
10. Peres MF, Stiles MA, Oshinsky M, et al. Remitting form of hemicrania continua with seasonal pattern. Headache 2001 Jun; 41 (6): 592-4
11. Gimeno MF, Landa A, Sterin-Speziale N, et al. Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur J Pharmacol 1980 Apr 4; 62 (4): 309-17
12. Nagtegaal JE, Smits MG, Swart ACW, et al. Melatonin- responsive headache in delayed sleep phase syndrome: preliminary observations. Headache 1998; 38: 303-7
13. Reiter RJ, Calvo JR, Karbownik M, et al. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000; 917: 376-86
14. Chuang JI, Mohan N, Meltz ML, et al. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int 1996 Oct; 20 (10): 687-92
15. Viswanathan M. Melatonin inhibits calcitonin gene-related peptide- induced vasodilation and increase in cAMP in rat middle cerebral arteries. Eur J Pharmacol 2001; 415: 247-50
16. Tom B, De Vries P, Heiligers JPC, et al. The lack of vasoconstrictor effect of the pineal hormone melatonin in an animal model predictive of antimigraine activity. Cephalalgia 2001 Jul; 21 (6): 656-63
17. Doolen S, Krause DN, Dubocovich ML, et al. Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 1998 Mar 12; 345 (1): 67-9
18. Wang F, Li JC, Wu CF, et al. Hypnotic activity of melatonin: involvement of semicarbazide hydrochloride, blocker of synthetic enzyme for GABA. Acta Pharmacol Sin 2002 Sep; 23 (9): 860-4
19. Li S, Wang T, Wang R, et al. Melatonin enhances antinociceptive effects of δ-, but not μ- opioid agonist in mice. Brain Res 2005; 1043: 132-8
20. Shavali S, Begonia H, Govitrapong P, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of β- endorphin an endogenous opioid. Brain Res Bull 2005; 64: 471-9
21. Castro LM, Gallant M, Niles LP. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005 Dec; 95 (5): 1227-36
22. Claustrat B, Loisy C, Brun J, et al. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache 1989 Apr; 29 (4): 242-5
23. Murialdo G, Fonzi S, Costelli P, et al. Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia 1994; 14: 205-9
24. Claustrat B, Brun J, Geoffriau M, et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997; 17: 511-7
25. Salvesen R, Bekkelund SI. Migraine, as compared to other headaches, is worse during midnight-sun summer than during polar night: a questionnaire study in an arctic population. Headache 2000; 40: 824-9
26. Claustrat B, Brun J, Chiquet C, et al. Melatonin secretion is supersensitive to light in migraine. Cephalalgia 2004; 24: 128-33
27. Micromedex®. Melatonin: Drugdex evaluations. Micromedex® Healthcare Series [online]. Available from URL: http://www.Thomson.hc.com [Accessed 2005 Dec]
28. Aldhous M, Franey C, Wright J, et al. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 1985 Apr; 19 (4): 517-21
29. Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep 1994 Oct; 17 (7): 638-45
30. Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3mg, is effective for migraine prevention. Neurology 2004 Aug 24; 63 (4): 757
31. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301-10
32. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, et al. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003; 8: D1093-108